Highlights

亮点

Fortrea completes acquisition of the Early Phase Services division from Worldwide Clinical Trials

Fortrea完成对Worldwide Clinical Trials早期阶段服务部门的收购

Adds a 60,000-square-foot GLP-compliant bioanalytical laboratory in Austin, Texas; a 200-bed GCP-compliant clinical pharmacology unit in San Antonio, Texas; and a biospecimen storage facility in Pflugerville, Texas

在德克萨斯州奥斯汀增加一个60,000平方英尺的符合GLP标准的生物分析实验室；在德克萨斯州圣安东尼奥增加一个200床位的符合GCP标准的临床药理学单元；以及在德克萨斯州普夫卢格维尔增加一个生物样本存储设施

Expands Fortrea’s early clinical development capacity to more than 570 beds globally and adds dedicated large and small molecule bioanalytical capabilities

将Fortrea的早期临床开发能力扩展至全球超过570张床位，并增加专用的大分子和小分子生物分析能力

Enables more integrated execution of early-phase studies by reducing operational handoffs between clinical and bioanalytical functions

通过减少临床与生物分析职能之间的操作交接，实现早期阶段研究更一体化的执行

Strengthens Fortrea’s end-to-end clinical development platform supporting clients from first-in-human studies through Phase IV and post-approval evidence generation

强化 Fortrea 的一体化临床开发平台，支持客户从首次人体试验到 IV 期临床试验及上市后证据生成的全过程

Supports Fortrea’s growth strategy by scaling early clinical development capabilities, increasing clinical research unit capacity and enhancing the company’s ability to create long-term value for shareholders

通过扩大早期临床开发能力、增加临床研究单位容量，并增强公司为股东创造长期价值的能力，支持Fortrea的增长战略

Provides continuity of operations, study delivery and client support throughout the transition through a strategic alliance agreement between the companies

通过公司间的战略联盟协议，在过渡期间确保运营、研究交付和客户支持的连续性

DURHAM, N.C., Oct. 19, 2026 (GLOBE NEWSWIRE) --

北卡罗来纳州达勒姆，2026年10月19日（环球电讯社）——

Fortrea

福特雷亚

(Nasdaq: FTRE) (the “Company”), a leading global contract research organization (“CRO”), today announced it has completed its acquisition of the Early Phase Services division from Worldwide Clinical Trials. The division consists of a Clinical Research Unit (“CRU”) and Bioanalytical Laboratory operations, in an all-cash transaction valued at approximately $45 million..

（纳斯达克股票代码：FTRE）（以下简称“公司”），一家全球领先的合同研究组织（“CRO”），今日宣布已完成从Worldwide Clinical Trials收购其早期阶段服务部门的交易。该部门包括一个临床研究单元（“CRU”）和生物分析实验室业务，这是一笔全现金交易，价值约为4500万美元。

The acquisition strengthens Fortrea’s end-to-end clinical development platform by adding a 200-bed Good Clinical Practice-compliant CRU in San Antonio, Texas; a 60,000-square-foot Good Laboratory Practice-compliant bioanalytical laboratory in Austin, Texas; and a biospecimen storage facility in Pflugerville, Texas.

此次收购通过增加以下设施，强化了Fortrea的一体化临床开发平台：位于德克萨斯州圣安东尼奥市的一家拥有200张床位、符合药物临床试验质量管理规范（GCP）的临床研究单位（CRU）；位于德克萨斯州奥斯汀市的一家面积达60,000平方英尺、符合药物非临床研究质量管理规范（GLP）的生物分析实验室；以及位于德克萨斯州普夫卢格维尔市的一处生物样本存储设施。

Together, these assets expand Fortrea’s early-phase capacity to more than 570 beds globally and add in-house large and small molecule bioanalytical capabilities to support clients from first-in-human studies through proof-of-concept and later-stage development..

这些资产共同将Fortrea的早期阶段临床容量扩展至全球超过570张床位，并增加了内部的大分子和小分子生物分析能力，以支持客户从首次人体试验到概念验证及后期开发的全过程。

“Completing this acquisition further strengthens our integrated, scalable and scientifically differentiated clinical development platform,” said Anshul Thakral, CEO of Fortrea. “This transaction demonstrates tangible progress in Fortrea’s return to growth as we invest in our ability to win new opportunities and create lasting value for clients.

“完成此次收购将进一步巩固我们一体化、可扩展且具备科学差异化的临床开发平台，”Fortrea 首席执行官 Anshul Thakral 表示。“此次交易彰显了 Fortrea 在回归增长轨道方面取得的实质性进展，因为我们正致力于提升赢得新机遇的能力，并为客户创造持久价值。”

By bringing together complementary clinical pharmacology and bioanalytical capabilities, we expect to expand the speed, flexibility and talent we can offer clients as they advance increasingly complex development programs. We are pleased to welcome the Early Phase Services team to Fortrea and look forward to delivering a seamless experience for clients, volunteers and the patients we ultimately serve.”.

通过整合互补的临床药理学和生物分析能力，我们期望在客户推进日益复杂的开发项目时，提升我们为其提供的速度、灵活性和人才支持。我们很高兴早期阶段服务团队加入福创医药（Fortrea），并期待为客户、志愿者以及我们最终服务的患者提供无缝衔接的服务体验。

“With this investment, Fortrea adds capability and capacity in its commitment to help clients design and execute early development programs with greater speed, scientific rigor and operational connectivity,” said Scott Dove, Ph.D., president, Clinical Pharmacology Services at Fortrea. “The addition of dedicated bioanalytical capabilities and expanded CRU capacity gives our teams more ways to support both simple and complex studies, streamline execution and generate high-quality data that inform development decisions.”.

“通过此次投资，Fortrea增强了其在帮助客户以更快速度、更严谨的科学性和更高效的运营协同性来设计和执行早期开发项目方面的能力与容量，”Fortrea临床药理学服务总裁Scott Dove博士表示。“新增的专用生物分析能力和扩展的临床研究单位（CRU）容量，使我们的团队能够以更多方式支持简单和复杂的研究，简化执行流程，并生成高质量数据，为开发决策提供依据。”

The addition of these capabilities complements Fortrea’s existing Clinical Pharmacology Services business and broadens its North American CRU footprint. The combined platform is designed to reduce operational handoffs between clinical and bioanalytical functions, improve turnaround times and provide clients with greater flexibility for complex and larger participant studies, broader access to distinct volunteer populations and expanded bedspace capacity across Fortrea’s early development network..

这些能力的加入补充了Fortrea现有的临床药理学服务业务，并扩大了其在北美的临床研究单位（CRU）布局。整合后的平台旨在减少临床与生物分析功能之间的操作交接，缩短周转时间，并为客户提供更大的灵活性，以应对复杂且规模更大的受试者研究，同时提供更广泛的独特志愿者人群访问渠道，并扩大Fortrea早期开发网络中的床位容量。

Fortrea and Worldwide Clinical Trials have also entered into agreements intended to support continuity for clients, employees and ongoing programs. Both organizations remain focused on maintaining project momentum and providing a seamless transition for employees, clients and volunteers.

Fortrea 与 Worldwide Clinical Trials 也已达成协议，旨在为客户、员工及正在进行的项目提供连续性保障。双方机构仍致力于保持项目推进势头，并为员工、客户和志愿者实现无缝过渡。

The acquired Early Phase Services operations are now part of Fortrea’s Clinical Pharmacology Services business unit.

被收购的早期阶段服务业务现已纳入Fortrea的临床药理学服务事业部。

Advisors

顾问

Barclays served as financial advisor to Fortrea, and Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. served as its legal counsel.

巴克莱银行担任富创得的财务顾问，明茨、莱文、科恩、费里斯、格洛夫斯基和波佩奥律师事务所（Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.）担任其法律顾问。

About Fortrea

关于 Fortrea

Fortrea (Nasdaq: FTRE) is a leading global provider of clinical development solutions to the life sciences industry. We partner with emerging and large biopharmaceutical, biotechnology, medical device and diagnostic companies to drive healthcare innovation that accelerates life changing therapies to patients.

Fortrea（纳斯达克股票代码：FTRE）是全球领先的生命科学行业临床开发解决方案提供商。我们与新兴及大型生物制药、生物技术、医疗器械和诊断公司合作，推动医疗创新，加速将改变患者生活的疗法推向市场。

Fortrea provides phase I-IV clinical trial management, clinical pharmacology and consulting services. Fortrea’s solutions leverage three decades of experience spanning more than 20 therapeutic areas, a passion for scientific rigor, exceptional insights and a strong investigator site network. Our talented and diverse team working in about 100 countries is scaled to deliver focused and agile solutions to clients globally.

Fortrea 提供 I-IV 期临床试验管理、临床药理学及咨询服务。Fortrea 的解决方案依托于三十余年横跨二十多个治疗领域的丰富经验、对科学严谨性的执着追求、卓越的洞察力以及强大的研究者站点网络。我们才华横溢且多元化的团队遍布全球约 100 个国家，具备为全球客户提供专注且敏捷解决方案的能力。

Learn more about how Fortrea is streamlining drug development at .

了解更多关于 Fortrea 如何简化药物开发的信息，请访问 。

Fortrea.com

Fortrea.com

and follow us on

并在以下平台关注我们

LinkedIn

领英

,

，

X

X

and

和

Bluesky

蓝天

.

。

Cautionary Statement Regarding Forward-Looking Statements

关于前瞻性陈述的警示性声明

This press release contains “forward-looking statements” within the meaning of the federal securities laws, including Section 27A of the Securities Act and Section 21E of the Exchange Act. Forward-looking statements by their nature address matters that are, to different degrees, uncertain, such as statements about the anticipated benefits of the transaction, including future financial and operating performance, and the anticipated timing for completing the transaction.

本新闻稿包含联邦证券法律（包括《证券法》第27A条和《交易法》第21E条）所定义的“前瞻性陈述”。前瞻性陈述本质上涉及不同程度的不确定性事项，例如关于交易预期益处的陈述，包括未来的财务和经营业绩，以及完成交易的预期时间。

In this context, forward-looking statements often address expected future business and financial performance and financial condition, and often contain words such as “guidance,” “expect,” “assume,” “anticipate,” “intend,” “plan,” “forecast,” “believe,” “seek,” “see,” “will,” “would,” “target,” similar expressions, and variations or negatives of these words that are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

在此背景下，前瞻性陈述通常涉及预期的未来业务和财务表现及财务状况，并常常包含“指引”、“预期”、“假设”、“预计”、“打算”、“计划”、“预测”、“相信”、“寻求”、“展望”、“将”、“将会”、“目标”等词语、类似表述以及这些词语的变体或否定形式，旨在识别前瞻性陈述，尽管并非所有前瞻性陈述都包含这些识别性词语。

Actual results could differ materially from these forward looking statements due to a number of factors, including, but not limited to:  the parties’ ability to meet expectations regarding the accounting and tax treatments of the proposed transaction; the anticipated benefits of the acquisition may not be realized, or may be realized more slowly or to a lesser extent than expected, difficulties, delays, costs or disruptions associated with integrating the acquired business, operations, employees, systems and processes into the Company, the ability to retain existing customers and business relationships of the acquired operations and win new business following the acquisition, the ability to retain and integrate key employees of the acquired business, the parties’ ability to perform their respective obligations under tran.

实际结果可能因多种因素而与这些前瞻性陈述存在重大差异，包括但不限于：各方能否满足对拟议交易的会计和税务处理的预期；收购的预期收益可能无法实现，或实现速度慢于预期或程度低于预期；与被收购业务、运营、员工、系统和流程整合至公司相关的困难、延迟、成本或中断；保留被收购业务的现有客户和业务关系以及在收购后赢得新业务的能力；保留并整合被收购业务关键员工的能力；各方履行其在交易项下各自义务的能力。

www.sec.gov

www.sec.gov

. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included or incorporated by reference in this report and in the Company’s filings with the SEC. All forward-looking statements are made only as of the date of this report and the Company does not undertake any obligation, other than as may be required by law, to update or revise any forward-looking statements to reflect future events or developments. .

。这些因素不应被视为详尽无遗，应结合本报告以及公司向美国证券交易委员会（SEC）提交的文件中包含或通过引用纳入的其他警示性声明一并阅读。所有前瞻性陈述仅以本报告日期为准，除非法律另有要求，公司不承担任何更新或修订任何前瞻性陈述以反映未来事件或发展的义务。。

Fortrea Contacts

Fortrea 联系方式

Galen Wilson (Media) – 703-298-0802,

盖伦·威尔逊（媒体）– 703-298-0802，

media@fortrea.com

media@fortrea.com

Kate Dillon (Media) – 646-818-9115,

凯特·迪伦（媒体）– 646-818-9115，

kdillon@prosek.com

kdillon@prosek.com

Tracy Krumme (Investors) – 984-385-6707,

Tracy Krumme（投资者）– 984-385-6707，

Tracy.Krumme@fortrea.com

Tracy.Krumme@fortrea.com